
ETCTN Trials by Disease/Treatment Area: Genitourinary Cancer



NOTE: * No ClinicalTrials.gov webpage is available currently (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide

ETCTN Genitourinary Cancer Trials (Open as of 9/10/2026)

Protocol Number	Phase	Protocol Title
10301	I/II	A Phase I and Randomized Phase II Trial of Radium-223 Dichloride, M3814, & Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
10466	II	A Phase II Study of Bevacizumab, Erlotinib and Atezolizumab in Subjects with Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Associated or Sporadic Papillary Renal Cell Cancer
10487	II	A Phase II Study of Lutetium Lu 177 Dotatate in Metastatic Prostate Cancer with Neuroendocrine Differentiation
10636	I	Phase 1 Trial of CA-4948 in Combination with Pembrolizumab to Overcome Resistance to PD-1/PD-L1 Blockade in Metastatic Urothelial Cancer
10743	Pilot	Pilot Phase II Trial Evaluating Safety and Feasibility of Neoadjuvant Botensilimab and Balstilimab in Clear Cell Renal Cell Carcinoma (NEO RoBOT)
10771	II	CHAMPION (CHeckpoint Inhibition in UrotheliAl Carcinoma with Mismatch RePair DefIciency or MicrOsatellite INstability)
10790	II	A Phase II Study of Enzomenib in Metastatic Castration-Resistant Prostate Cancer
10786	II	Randomized Phase II Study of Triapine Plus Lutetium-177 PSMA-617 vs. Lutetium-177 PSMA-617 in Metastatic Castration-Resistant Prostate Cancer After Progression on One Prior Androgen Receptor Pathway Inhibitor